Please login to the form below

Not currently logged in
Email:
Password:

Bayer’s former oncology head Robert Rosen joins AP Pharma

Will lead launch of drug to prevent chemotherapy-induced nausea

AP Pharma has appointed the former global head of oncology at Bayer Healthcare Robert Rosen as its new senior VP and chief commercial officer.

In this role he will lead efforts at the US-based specialty pharma company to launch APF530 – AP Pharma's lead product candidate for the prevention of chemotherapy-induced nausea and vomiting.

If the drug does successfully make it onto the market, Rosen will also serve as a director of the company, AP Pharma said.

“We are delighted to bring Robert on to the AP Pharma management team,” said John Whelan, president and CEO of the company. “Robert's deep and extensive experience commercialising oncology drugs will be instrumental as we enter the commercialisation phase of the company.”

This experience includes his time leading Bayer's efforts in cancer from 2005 to 2011.

During this time, he led the launch of Nexavar (sorafenib), which made more than $1bn last year, for the treatment of renal cell carcinoma and hepatocellular carcinoma.

Rosen also led premarket activities for Stivarga (regorafenib) in its indications for gastrointestinal stromal tumours and colon cancer, as well as for alpharadin in prostate cancer.

Prior to joining Bayer, Rosen was VP of the oncology business unit at Sanofi-Synthèlabo, where he helped develop Sanofi's cancer footprint in the US with the launch of Eloxatin (oxaliplatin) for colon cancer.

19th October 2012

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Red Door Communications

Red Door Communications (RDC) is the health and wellbeing communications consultancy that lives and breathes originality and is built on...

Latest intelligence

Easier access to medicines in the UK?
Cutting through the NICE value-based assessment consultation to find out what’s at stake...
Exploring MINT: Part 3 - Nigeria
In the third of a series of posts focusing on each of the ‘MINT’ markets, I take an in-depth look at the opportunities and challenges for pharma in Nigeria....
BL_Where_Now_20140721_CoverImage.jpg
3 Steps to Navigating Multichannel in Healthcare
You know about multichannel, but... where now? Download the 3 Steps to Navigating Multichannel in Healthcare ebook to learn what you should do next when planning your multichannel campaign....